• Hereditary breast cancer: new genetic developments, new therapeutic avenues
  Campeau PM, Foulkes WD, Tischkowitz MD
  
  http://www.ncbi.nlm.nih.gov/pubmed/18575892

• Breast cancer genes: therapeutic strategies
  Holt JT
  
  http://www.ncbi.nlm.nih.gov/pubmed/9616738

• Cancer pharmacogenomics: DNA genotyping and gene expression profiling to identify molecular determinants of chemosensitivity
  Auman JT, McLeod HL
  
  http://www.ncbi.nlm.nih.gov/pubmed/18559613

• Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics
  Rubinstein WS
  
  http://www.ncbi.nlm.nih.gov/pubmed/17624601
  
  

• PARP inhibitor development for systemic cancer targeting
  Zaremba T, Curtin NJ
  
  http://www.ncbi.nlm.nih.gov/pubmed/17896912

• Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
  Vol 25, No 18S (June 20 Supplement), 2007: 3529
  © 2007 American Society of Clinical Oncology

• First in human phase I pharmakinetic (PK) and phramacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers.
  Yap TA, Boss DS, Fong PC, Roelvink M, Tutt A, Carmichael J, O’Connor MJ, Kaye SB, Shellens JH, de Bono JS
  
  http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/3529

Privacy Statement    |    Terms of Use    |    Webmaster    |    Contact TGI    |    © Tissue genetics inc. 2000-2008